Search Results for keywords:"hearing requests"

The Nuclear Regulatory Commission (NRC) has issued a regular monthly notice under the Atomic Energy Act, allowing amendments to nuclear facility licenses that pose no significant hazards. The period covered for these amendments is from November 7, 2024, to December 5, 2024. The public can comment on these amendments until January 22, 2025, and request hearings until February 21, 2025. For additional information and to make comments, the NRC encourages using electronic submissions through the federal rulemaking website.

The Securities and Exchange Commission (SEC) has released a notice about an application by Guardian Variable Products Trust and Park Avenue Institutional Advisers LLC. They are seeking an exemption from the requirement of the Investment Company Act of 1940 that mandates in-person meetings for approving new or amended sub-advisory agreements. The application was filed on December 13, 2024, and the SEC may hold a hearing if requested by interested parties. Hearing requests must be submitted to the SEC by February 18, 2025.

Groff NA Hemplex LLC has applied to the Drug Enforcement Administration to become a registered importer of certain controlled substances. These substances will be imported in bulk to produce research-grade materials for clinical trial studies, specifically involving Marihuana Extract compounds. The application process allows for public comments or objections and requests for a hearing until January 13, 2025. The comments should be submitted electronically through the Federal eRulemaking Portal, while hearing requests must be directed to the DEA's office in Springfield, Virginia.

The Securities and Exchange Commission (SEC) is announcing a notice regarding applications for deregistration under Section 8(f) of the Investment Company Act of 1940, specifically for February 2025. A unit investment trust, named FSL Separate Account M, has applied for an order declaring that it is no longer an investment company, as it currently has 96 beneficial owners and does not offer or plan to offer securities. The filing for this application was made on July 1, 2024, and the applicant operates as a private investment fund under section 3(c)(1) of the Act. Public comments or hearing requests can be submitted until March 25, 2025.

Janssen Pharmaceuticals Inc. has filed an application with the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances for analytical purposes. Public comments or objections regarding this application are accepted until March 17, 2025. Hearings can also be requested by this date. Comments should be submitted via the Federal eRulemaking Portal, and requests for hearings must be sent to the DEA at specified addresses.

The Nuclear Regulatory Commission (NRC) published a monthly notice in accordance with the Atomic Energy Act, outlining proposed amendments to facility operating licenses and combined licenses. These amendments are considered to involve no significant hazards consideration (NSHC) and are effective immediately if determined appropriate by the NRC. Interested parties can submit comments or request hearings by the specified deadlines of April 17, 2025, and May 19, 2025, respectively. Information on obtaining documents and submitting comments is available through various methods, including the NRC's electronic systems.

Lonza Tampa, LLC has applied to the Drug Enforcement Administration to become registered as an importer of controlled substances, specifically focusing on the drug code 7437 (Psilocybin). They plan to use Psilocybin as a bulk active pharmaceutical ingredient for clinical trials, research, and analytical purposes. The DEA is allowing registered bulk manufacturers or applicants to submit electronic comments or objections to this application by March 20, 2025. Requests for a hearing can also be submitted by this date.

The Nuclear Regulatory Commission (NRC) is releasing a monthly notice regarding amendments to facility operating licenses and combined licenses under the Atomic Energy Act of 1954. These amendments involve no significant hazards consideration (NSHC), meaning they don't significantly increase risk or create new accident possibilities. Public comments are invited, and people can request a hearing if they believe they would be impacted by these changes. The NRC emphasizes the use of their electronic filing system for submitting documents related to these proceedings.

Siegfried USA, LLC has applied to the Drug Enforcement Administration (DEA) to become a registered manufacturer of certain controlled substances in bulk. This application was submitted on December 9, 2020. Interested parties can submit comments, objections, or requests for a hearing regarding this application by March 15, 2021. The purpose of this registration is for Siegfried USA, LLC to produce these substances for sale to their customers, and no other activities with these drugs are permitted under this registration.

Vici Health Sciences, LLC has applied to become an importer of specific controlled substances to support their research and clinical trials. The Drug Enforcement Administration (DEA) is accepting public comments and objections to this application until February 27, 2025. Interested parties can submit their comments electronically through the Federal eRulemaking Portal. The DEA has specified that this permit will not authorize the import of finished medication forms for sale.